Opsonophagocytic activity (OPA) of pneumococcal polysaccharide (Pnc PS) antibodies in vitro, a measure of antibody functional activity, usually correlates with specific IgG antibody concentrations measured by an EIA method. In order to investigate the functional activity of specific Pnc PS antibodies, we determined IgG antibodies to Pnc PS type 19F by an EIA method and OPA against Pnc type 19F by a killing assay in a randomized study, where 23 adult allogeneic BMT recipients were vaccinated with Pnc PS vaccine at 8 months (early group) and 21 recipients at 20 months (late group) after transplantation. Serum samples drawn before BMT, before vaccination, and at 1 and 16 months after vaccination were available from 27, 35, 34 and 30 patients, respectively. The geometric mean antiPnc 19F concentrations were 4.3, 1.3, 1.6 and 1.3 g/ml in the early group and 3.8, 0.9, 0.6 and 0.6 g/ml in the late group before transplantation, before vaccination, and at 1 and 16 months after vaccination, respectively. OPA (titre у8) was found in 10/27, 5/35, 5/34 and 6/30 patients before BMT, before vaccination, and at 1 and 16 months after vaccination, respectively. The specific IgG antibody concentration and OPA correlated with each other before BMT, and in the early group patients before and at 1 month after vaccination. The results demonstrate that after Pnc PS vaccination allogeneic BMT recipients have antibodies with low functional activity to a Pnc PS antigen associated with low specific IgG responses. There is a need to study new Pnc conjugate vaccines in multi-dose schedules for their capacity to elicit higher specific antibody concentrations with high OPA in BMT recipients. Bone Marrow Transplantation (2001) 27, 207-211. Keywords: opsonophagocytic activity; BMT recipients; pneumococcal antibodies Streptococcus pneumoniae (Pnc) is the main cause of bacterial infections in allogeneic BMT recipients surviving Ͼ3
months after transplantation. [1] [2] [3] [4] [5] [6] [7] [8] [9] Pnc causes infections with exceptional clinical manifestations in BMT recipients. 10, 11 Pnc infections have been described after stem cell transplantation in patients vaccinated with Pnc polysaccharide (PS) vaccine early after transplantation. 8, 12 The ability of allogeneic BMT recipients to respond to vaccines composed of plain PS antigens is poor, when measured as antibody concentrations before and after vaccination. [12] [13] [14] [15] [16] [17] [18] Besides low specific antibody levels, impaired opsonization of Streptococcus pneumoniae by specific antibodies and functional hyposplenism may be responsible for Pnc infections in BMT recipients. 2, 19, 20 Protection against Pnc infections is mainly mediated by opsonin-dependent phagocytosis. 21, 22 Therefore, opsonophagocytic activity (OPA) of Pnc PS antibodies is considered an in vitro measure of functional antibody activity. The aim of the present study was to assess the functional activity of antibodies in allogeneic BMT recipients immunized with Pnc PS vaccine using an opsonophagocytic assay for Pnc serotype 19F and to correlate this with IgG antiPnc 19F PS concentrations to find out whether these predict the OPA.
Materials and methods

Patients, vaccinations and serum samples
In a randomized study 45 adult BMT recipients who received a bone marrow transplant from an HLA-identical, MLC-negative sibling donor were vaccinated according to two different vaccination schedules, starting either at 6 (early group) or 18 (late group) months after transplantation as described previously. 23 Briefly, depending on the vaccination group, the patients received Pnc PS vaccine (Pneumovax; Merck, Sharp and Dohme, West Point, PA, USA) either at 8 or 20 months after BMT. All 20 early group patients and three out of 14 late group patients with serum samples available at 1 month after vaccination were on immunosuppressive therapy for the 2 months before vaccination or at the time of vaccination. Nine early group patients and two late group patients had clinical symptoms or signs of chronic GVHD between 2 months prior to vaccination and the time of vaccination. One patient in both vaccination groups had extensive chronic GVHD. Three late group patients received intravenous immunoglobulin during the first 3 months after BMT, but none did so later. The total anti-Pnc 19F PS concentrations had been determined in our previous study, 23 and the IgG anti-Pnc 19F concentrations were measured for the present study in the sera from patients with serum samples still available. Serum samples drawn from 27, 35, 34 and 30 patients were available before transplantation, before vaccination, and at 1 and 16 months after vaccination, respectively.
EIA for IgG Pnc 19F PS antibodies and opsonophagocytic assay
The concentrations of IgG antibodies to Pnc PS 19F were measured by enzymeimmunoassay (EIA) described previously by Käyhty et al. 24 The results are given as g/ml calculated on the basis of the officially assigned IgG values of the 89-SF reference serum. 25 The lower detection limit for IgG anti-19F was 0.17 g/ml. OPA against type 19F pneumococcus was determined by a killing assay using fresh human polymorphonuclear leucocytes and baby rabbit complement as described by Anttila et al. 26 OPAs are expressed as titres: OPA is the reciprocal of the serum dilution with 50% killing as compared to the bacterial growth in controls without serum. A titre of 4 was given to sera with undetectable OPAs, the titre of 8 being the lowest positive result.
Statistical methods
Correlations between the log-transformed IgG anti-19F PS concentration and OPA were tested by using Pearson's correlation coefficient.
Results
The geometric mean concentrations of IgG Pnc type 19F antibodies were 4.30, 1.33, 1.60 and 1.30 g/ml in the early group patients and 3.75, 0.86, 0.58 and 0.59 g/ml in the late group patients before transplantation, before vaccination, and at 1 and 16 months after vaccination, respectively. OPA (titre у8) was detectable in six out of 17 (35%), in three out of 19 (16%), in five out of 20 (25%), and in five out of 18 (28%) serum samples drawn from the early group patients before BMT, before vaccination, and at 1 and 16 months after vaccination. OPA was detectable in four out of 10 (40%), in two out of 16 (12.5%), in none out of 14, and in one out of 12 (8%) sera drawn from the late group patients before transplantation, before vaccination, and at 1 and 16 months after vaccination.
Twelve BMT recipients out of 28 with serum samples available both before and after vaccination for the determination of the total and/or IgG antibody response showed у30% higher anti-19F 1 month after vaccination compared to the prevaccination concentration (Table 1) . Sixteen patients had Ͻ30% increase in the IgG and total anti-19F concentration. Even among patients with у30% response to Pnc PS vaccine no detectable OPA was found in six out of nine serum samples drawn before transplantation, in nine out of 11 serum samples taken before vaccination, and in nine out of 12 serum samples drawn at 1 month after vaccination (Table 1) . Patient No. 31 showed no OPA despite IgG anti-19F concentrations Ͼ10 g/ml in all measurements.
Three patients showed an increase in OPA after vaccination. All were vaccinated at 8 months after BMT. Patient No. 49 had no serum sample for measurement of the IgG anti-19F concentration and OPA immediately before vaccination, but her specific IgG concentration and OPA were lower before BMT than after vaccination and the total antiPnc 19F concentration increased after vaccination suggesting that also this patient had an IgG response. Patient No. 31 with limited GVHD had an IgG antibody concentration of 16 g/ml after immunization, but OPA was not detected.
In the whole patient population, in patients with at least one serum sample available prior to BMT, before vaccination, 1 or 16 months after vaccination, the specific IgG concentrations ranged from the detection level of 0.17 g/ml to 20.34 g/ml and the OPA from undetectable (titre 4) to 861. Prior to transplantation there was a correlation between the IgG anti-19F PS concentration and OPA in the sera from the early and late group patients (Figure 1) . A correlation between the IgG Pnc 19F antibody concentration and OPA was also seen in the sera from the early group patients before and 1 month after vaccination (Figure 1 ). In the late group patients OPA was detected only in two sera drawn before and in no sera drawn 1 month after vaccination, and the correlations between IgG and OPA could not be calculated. Statistically significant correlations between the specific IgG concentrations and OPA were not detected in the sera drawn 16 months after vaccination.
Discussion
This study shows that sera drawn from adult BMT recipients transplanted from an HLA-identical sibling donor have low OPA for Pnc serotype 19F both before and after vaccination with Pnc PS vaccine. The IgG concentrations of antibodies to Pnc 19F PS may be used as a surrogate measure of OPA in BMT recipients before and 1 month after vaccination.
Only three out of 34 recipients with serum samples available at 1 month after vaccination in the present study had shown at least a two-fold total anti-Pnc 19F response to the Pnc PS vaccine. 23 Opsonin-dependent phagocytosis is the major defence mechanism against Streptococcus pneumoniae. 21, 22 Because the functional activity of specific antibodies may be especially important at low antibody concentrations, OPA was measured in all serum samples available at 1 month after vaccination, regardless of the response to the vaccine. Five patients showed OPA, and two of them had shown a clear increase in the total antibody concentration after vaccination. OPA was detectable at 1 month after vaccination only in the sera collected from the patients vaccinated at 8 months after BMT. However, as only two thirds of all possible serum samples from the patients vaccinated at 20 months after BMT were available at 1 month after vaccination, it cannot be firmly concluded that early vaccination elicits PS antibodies with higher OPA than vaccination late after BMT. The poor OPA against Pnc type 19F in sera collected from the present patients after vacci- No chronic GVHD; c limited chronic GVHD; e extensive chronic GVHD. b Determined in sera collected before BMT. d 1.5-fold increase in total antibody concentration after vaccination. IgG = specific IgG anti-19F concentration (g/ml); OPA = opsonophagocytic activity (titre). nation supports the poor immunogenicity of the Pnc PS vaccine in BMT recipients as has been shown earlier by measuring total anti-Pnc PS concentrations. In normal adults the OPA of antibodies to Pnc serotypes 6B, 14, 19F, and 23F correlates with specific IgG, IgG1 and IgG2 antibody levels, but not with specific IgA and IgM levels. [26] [27] [28] IgG anti-19F PS concentrations у1-2 g/ml are needed to detect the OPA by the methodology we used. 26 In this study the 12 BMT recipients showing any response to Pnc PS vaccine achieved low IgG anti-19F concentrations. This may partly explain the fact that regardless of IgG anti-19F increases there were no changes in the OPA in many cases.
To our knowledge, serum opsonic activity has not been studied earlier in BMT recipients after vaccination with Pnc PS vaccine. In this study it was found that the increases in the anti-Pnc 19F concentrations after vaccination with Pnc PS vaccine are generally too low to improve the detection of the OPA measured in vitro. However, in some patients the OPA was measurable after vaccination, suggesting that if sufficient increases in antibody concentrations are achieved these antibodies will function as opsonins. Winston et Bone Marrow Transplantation al 2 measured serum opsonic activity against Streptococcus pneumoniae serotype 6A in seven allogeneic BMT recipients with Pnc infection. Sera from six patients showed decreased OPA compared to normal pooled serum both before, during, and after the clinical infection episode. Four of their six patients with impaired opsonic activity had low serum antibody concentrations to Pnc type 6A. The other two patients with decreased opsonic activity had normal anti-Pnc 6A concentrations but low complement levels.
Patient No. 31 showed no OPA against Pnc type 19F in spite of satisfactory IgG antibody concentrations. Chronic GVHD cannot explain the lack of OPA, because opsonophagocytosis was already absent before BMT. In other patients with chronic GVHD, OPA was seen if the patient could produce enough IgG antibodies to enable the detection of OPA. All early group patients were on immunosuppressive therapy and, nevertheless, 25% showed detectable OPA after vaccination, in contrast to none of the late group patients without immunosuppression. In some cases polyreactive, non-specific antibodies with low functional activity can be detected by the EIA method, and explain the undetectable OPA in sera with high specific IgG levels. 29 In the study of Anttila and co-workers, 26 OPA against Pnc serotypes 6B, 19F and 23F was not detectable in most of the sera drawn from healthy adults without vaccination with Pnc vaccines whereas after immunization with plain Pnc PS or Pnc conjugate vaccines OPA was detectable in all serum samples. The IgG antibody concentrations to Pnc 19F showed a high degree of correlation with OPA, r values being 0.70 and 0.88 before and after vaccination, in contrast to 0.51 and 0.52 before and after vaccination in our study, respectively. The present patients showed a weaker correlation between the specific IgG concentrations and OPA before BMT and in the early group also immediately before and 1 month after vaccination with Pnc PS vaccine, probably due to the high proportion of sera with low specific IgG concentrations and undetectable OPA. None of the late group patients with a serum sample available 1 month after vaccination showed OPA, and no correlations between the specific IgG concentrations and OPA could be calculated.
In conclusion, OPA against Pnc 19F PS is, usually concomitantly with low specific IgG antibody, low in BMT recipients both before and after vaccination with Pnc PS vaccine. However, some patients show OPA after vaccination. It is possible that if higher specific IgG antibody concentrations can be achieved in BMT recipients by using new Pnc conjugate vaccines with multi-dose schedules, the OPA of antibodies would also increase.
